ALT Total Utang marang Modal Altimmune Corp

ALT (Altimmune Corp) - tandha merek perusahaan

Altimmune, Inc. (ALT) develops obesity and liver pathology treatments in US laboratories, leveraging advanced inhalation technologies and clinical trial phases. The business operates within an autonomous cycle independent of global economic fluctuations, transforming the sector into a resilient defensive asset. This price chart reflects a market trend for the asset with a debt-to-equity ratio of 0.08, underscoring the company's status as a developer of breakthrough peptides for metabolic correction.

ALT Rasio Kabeh Utang marang Dana Pribadi Altimmune (04.07.2022 - 28.10.2026)

Rincian analitis perusahaan Altimmune, Inc.

- rega lan prakiraan konsensus rega:
Rega saham Altimmune|ALT - Konsensus nilai wajar
- data kapitalisasi pasar:
Kapitalisasi pasar Altimmune|ALT - Nilai Perusahaan
- data kapitalisasi buku:
Aset Bersih saben Siji Saham Altimmune|ALT - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku altimmune.com|ALT - Gunggung Aset Perusahaan
- data utang lan likuiditas:
Total Utang marang Modal Altimmune, Inc.|ALT - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Altimmune, Inc.|ALT - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Altimmune|ALT - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan Altimmune
Ringkesan analisis perusahaan:Altimmune
Produk dadi altimmune.com

Long-term investing requires strict control over the liability structure to minimize bankruptcy risks. For Altimmune, Inc. (ALT), which is developing an innovative peptide platform against obesity, maintaining financial autonomy is critically important. Analyzing the company's history of financial leverage, we see the ratio of total borrowings to equity. This coefficient determines the degree of the business's dependence on external lending. A low value confirms capital stability and asset security.

Pesaing utama

ASND - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi Madrigal Pharmaceuticals Inc|Total Utang marang Modal CORT|Total Utang marang Modal RYTM (Rhythm Corp)|Utang marang Ekuitas Akero Therapeutics|metsera.com - Rasio Kabeh Utang marang Dana Pribadi|MLTX: Utang marang Ekuitas|CRNX - Rasio Total Utang marang Ekuitas|NAMS: Total Utang marang Modal|Total Utang marang Modal Soleno Therapeutics Corp|FOLD - Rasio Total Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi ETNB|Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|Rasio Total Utang marang Ekuitas Structure Therapeutics Inc (GPCR)|MDXG: Total Utang marang Modal|RZLT - Utang marang Modal|Rasio Total Utang marang Ekuitas Lexicon Pharmaceuticals LXRX|MBX - Utang Agregat marang Modal|AARD: Total Utang marang Modal|Sagimet Biosciences, Inc. (SGMT) - Total Utang marang Modal|Total Utang marang Modal BioAge Labs Inc.|Utang marang Ekuitas BMEA|Quince Therapeutics - Utang marang Ekuitas|Utang marang Modal GUTS (fractyl.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Utang marang Ekuitas Agape ATP Corp ATPC|Total Utang marang Modal PLUR (Pluri Inc)|SYBX: Koefisien Total Utang marang Modal|Lipocine Inc. - Utang marang Ekuitas|MTNB (Matinas BioPharma Holdings) - Koefisien Total Utang marang Modal|Utang marang Ekuitas SPRB|Rasio Total Utang marang Ekuitas Galecto Inc|Total Utang marang Modal CTCX|Total Utang marang Modal LUMO (Lumos Therapeutics)|Utang marang Ekuitas Organovo Holdings, Inc. ONVO|RDUS - Utang marang Ekuitas